TELO2

Across TCGA pan-cancer cohorts, TELO2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TELO2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher TELO2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TELO2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCS, UCEC, and LUAD are the cancer types where TELO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
UCEC	OS	Median	All	1.000	0.664	.014	26	view →
LUAD	OS	Median	III,IV	0.147	0.679	.001	15	view →
BLCA	DFS	Median	II,III,IV	1.000	0.498	.017	10	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.200	0.322	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TELO2–UCS (DFS)

Open the UCS breakdown →